Reverse share split proposed at EGM to meet NASDAQ listing criteria. Olpruva US launch in early July. US launches of PKU GOLIKE and Olpruva boost near-term revenue. Successful development of pipeline drugs, including RLF-100 in rare lung disease, RLF-OD032 in PKU, and RLF-TD011 in EB, boost long-term revenue.
Key catalysts include: